Ectopic ACTH Secretion clinical trials at University of California Health

1 in progress, 0 open to eligible people

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Sorry, not currently recruiting here
This is a randomized, placebo-controlled, crossover study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Subjects will receive each of the following 2 treatments for 12 weeks: SPI-62 and matching placebo
at UCLA

Our lead scientists for Ectopic ACTH Secretion research studies include Anthony Heaney, MD.

Last updated: January 26, 2023

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome